LYKALABSPharmaceuticals
Lyka Labs Ltd — Profit & Loss Statement
₹44.95
-9.04%
Lyka Labs Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Rate For Calcs | 0.29 | 0.30 | 0.00 | 0.35 | — |
| Normalized EBITDA | 19.96 Cr | 16.97 Cr | 20.09 Cr | 103.24 Cr | — |
| Total Unusual Items | 0.02 Cr | -0.41 Cr | -7.39 Cr | -6.52 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.02 Cr | -0.41 Cr | -7.39 Cr | -6.52 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 8.01 Cr | -2.49 Cr | -13.21 Cr | 39.00 Cr | — |
| Reconciled Depreciation | 6.77 Cr | 12.80 Cr | 14.15 Cr | 17.35 Cr | — |
| Reconciled Cost Of Revenue | 56.01 Cr | 45.19 Cr | 37.87 Cr | 53.30 Cr | — |
| EBITDA | 19.98 Cr | 16.56 Cr | 12.70 Cr | 96.73 Cr | — |
| EBIT | 13.21 Cr | 3.76 Cr | -1.45 Cr | 79.38 Cr | — |
| Net Interest Income | -1.81 Cr | -3.95 Cr | -9.72 Cr | -18.79 Cr | — |
| Interest Expense | 2.09 Cr | 4.69 Cr | 11.72 Cr | 20.13 Cr | — |
| Interest Income | 0.46 Cr | 0.86 Cr | 2.15 Cr | 1.34 Cr | — |
| Normalized Income | 7.99 Cr | -2.20 Cr | -5.83 Cr | 43.23 Cr | — |
| Net Income From Continuing And Discontinued Operation | 8.01 Cr | -2.49 Cr | -13.21 Cr | 39.00 Cr | — |
| Total Expenses | 122.38 Cr | 102.17 Cr | 85.59 Cr | 99.77 Cr | — |
| Rent Expense Supplemental | 1.78 Cr | 1.70 Cr | 1.49 Cr | 0.77 Cr | — |
| Diluted Average Shares | 3.56 Cr | 3.30 Cr | 2.88 Cr | 2.87 Cr | — |
| Basic Average Shares | 3.56 Cr | 3.30 Cr | 2.88 Cr | 2.87 Cr | — |
| Diluted EPS | 2.25 | -0.75 | -4.63 | 13.57 | — |
| Basic EPS | 2.25 | -0.75 | -4.63 | 13.57 | — |
| Diluted NI Availto Com Stockholders | 8.01 Cr | -2.49 Cr | -13.21 Cr | 39.00 Cr | — |
| Net Income Common Stockholders | 8.01 Cr | -2.49 Cr | -13.21 Cr | 39.00 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 8.01 Cr | -2.49 Cr | -13.21 Cr | 39.00 Cr | — |
| Minority Interests | 0.08 Cr | 0.13 Cr | -0.06 Cr | 0.56 Cr | — |
| Net Income Including Noncontrolling Interests | 7.93 Cr | -2.62 Cr | -13.15 Cr | 38.44 Cr | — |
| Net Income Continuous Operations | 7.93 Cr | -2.62 Cr | -13.15 Cr | 38.44 Cr | — |
| Tax Provision | 3.19 Cr | 1.69 Cr | -0.02 Cr | 20.80 Cr | — |
| Pretax Income | 11.12 Cr | -0.93 Cr | -13.17 Cr | 59.25 Cr | — |
| Other Non Operating Income Expenses | 0.70 Cr | 0.06 Cr | 0.79 Cr | 0.20 Cr | — |
| Special Income Charges | 0.00 | -0.41 Cr | -7.39 Cr | -6.52 Cr | — |
| Net Non Operating Interest Income Expense | -1.81 Cr | -3.95 Cr | -9.72 Cr | -18.79 Cr | — |
| Total Other Finance Cost | 0.19 Cr | 0.12 Cr | 0.15 Cr | — | 0.28 Cr |
| Interest Expense Non Operating | 2.09 Cr | 4.69 Cr | 11.72 Cr | 20.13 Cr | — |
| Interest Income Non Operating | 0.46 Cr | 0.86 Cr | 2.15 Cr | 1.34 Cr | — |
| Operating Income | 11.19 Cr | 2.96 Cr | 2.75 Cr | 83.82 Cr | — |
| Operating Expense | 66.37 Cr | 56.98 Cr | 47.72 Cr | 46.47 Cr | — |
| Other Operating Expenses | 19.16 Cr | 15.24 Cr | 12.93 Cr | 14.73 Cr | — |
| Depreciation And Amortization In Income Statement | 6.77 Cr | 12.80 Cr | 14.15 Cr | 17.35 Cr | — |
| Depreciation Income Statement | 6.77 Cr | 12.80 Cr | 14.15 Cr | 17.35 Cr | — |
| Research And Development | 0.98 Cr | 0.64 Cr | — | — | — |
| Selling General And Administration | 7.86 Cr | 5.78 Cr | 5.16 Cr | 5.97 Cr | — |
| Selling And Marketing Expense | 4.82 Cr | 3.28 Cr | 2.28 Cr | 2.77 Cr | — |
| General And Administrative Expense | 3.04 Cr | 2.51 Cr | 2.88 Cr | 3.20 Cr | — |
| Rent And Landing Fees | 1.78 Cr | 1.70 Cr | 1.49 Cr | 0.77 Cr | — |
| Gross Profit | 77.56 Cr | 59.94 Cr | 50.47 Cr | 130.28 Cr | — |
| Cost Of Revenue | 56.01 Cr | 45.19 Cr | 37.87 Cr | 53.30 Cr | — |
| Total Revenue | 133.56 Cr | 105.13 Cr | 88.34 Cr | 183.59 Cr | — |
| Operating Revenue | 133.56 Cr | 105.13 Cr | 88.34 Cr | 183.59 Cr | — |
| Tax Effect Of Unusual Items | 70576.65 | -0.12 Cr | -0.01 Cr | -2.29 Cr | — |
| Other Special Charges | — | 0.41 Cr | 7.64 Cr | 0.76 Cr | 0.73 Cr |
| Write Off | — | 0.00 | -0.25 Cr | 3.38 Cr | 0.11 Cr |
| Impairment Of Capital Assets | — | — | 0.00 | 2.38 Cr | 0.26 Cr |
| Amortization | — | — | — | 11.71 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Lyka Labs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.